Please use this identifier to cite or link to this item:
|Title:||Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial|
|Authors:||Gleeson, Mary;Hawkes, Eliza A;Cunningham, David;Chadwick, Nick;Counsell, Nicholas;Lawrie, Anthony;Jack, Andrew;Smith, Paul;Mouncey, Paul;Pocock, Christopher;Ardeshna, Kirit M;Radford, John;McMillan, Andrew;Davies, John;Turner, Deborah;Kruger, Anton;Johnson, Peter WM;Gambell, Joanna;Linch, David|
|Citation:||British Journal of Haematology 2016; online first: 1 August|
|Abstract:||We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.|
|Subjects:||Lymphoma, Large B-Cell, Diffuse|
|Type of Clinical Study or Trial:||Clinical Trial|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.